Crinetics Pharmaceuticals (CRNX) Resumen de Acciones
Crinetics Pharmaceuticals, Inc. es una empresa farmacéutica en fase clínica centrada en el descubrimiento, desarrollo y comercialización de nuevas terapias para enfermedades endocrinas raras y tumores relacionados con el sistema endocrino. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
CRNX Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Crinetics Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$42.23 |
| Máximo en las últimas 52 semanas | US$57.99 |
| Mínimo de 52 semanas | US$25.83 |
| Beta | 0.23 |
| Cambio en 1 mes | 28.28% |
| Variación en 3 meses | 12.02% |
| Cambio de 1 año | 41.71% |
| Variación en 3 años | 126.07% |
| Variación en 5 años | 101.19% |
| Variación desde la OPV | 72.30% |
Noticias y actualizaciones recientes
CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution
The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements
Summary Crinetics Pharmaceuticals maintains a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for acromegaly. The company advances atumelnant, its oral ACTH receptor antagonist, with promising phase 2 data for CAH and ACTH-dependent Cushing's syndrome. Q1 2026 Palsonify revenues reached $10.3M, beating expectations, but the company's cash runway remains limited to at least 12 months. Ongoing late-stage trials and global regulatory submissions for Palsonify and atumelnant underpin the investment thesis, despite dilution and execution risks. Read the full article on Seeking AlphaCrinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...Recent updates
CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution
The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements
Summary Crinetics Pharmaceuticals maintains a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for acromegaly. The company advances atumelnant, its oral ACTH receptor antagonist, with promising phase 2 data for CAH and ACTH-dependent Cushing's syndrome. Q1 2026 Palsonify revenues reached $10.3M, beating expectations, but the company's cash runway remains limited to at least 12 months. Ongoing late-stage trials and global regulatory submissions for Palsonify and atumelnant underpin the investment thesis, despite dilution and execution risks. Read the full article on Seeking AlphaCrinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...A Look At The Intrinsic Value Of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Key Insights The projected fair value for Crinetics Pharmaceuticals is US$37.65 based on 2 Stage Free Cash Flow to...Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking AlphaWe're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking AlphaMost Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Key Insights Crinetics Pharmaceuticals to hold its Annual General Meeting on 7th of June Salary of US$614.0k is part of...Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking AlphaRentabilidad de los accionistas
| CRNX | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 15.1% | 1.4% | 1.6% |
| 1Y | 41.7% | 48.6% | 18.6% |
Rentabilidad vs. Industria: Los resultados de CRNX fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 48.6% el año pasado.
Rentabilidad vs. Mercado: CRNX superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| CRNX volatility | |
|---|---|
| CRNX Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: CRNX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CRNX (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 594 | R. Struthers | www.crinetics.com |
Crinetics Pharmaceuticals, Inc. es una empresa farmacéutica en fase clínica centrada en el descubrimiento, desarrollo y comercialización de nuevas terapias para enfermedades endocrinas raras y tumores relacionados con el sistema endocrino. El principal producto candidato de la empresa es la paltusotina, un agonista oral selectivo no peptídico del receptor de somatostatina de tipo 2, que se encuentra en un ensayo clínico de fase 3 para el tratamiento de la acromegalia y el síndrome carcinoide asociado a tumores neuroendocrinos. También está desarrollando Atumelnant, un candidato a producto oral no peptídico en fase de investigación para antagonizar el receptor de la hormona adrenocorticotrófica (ACTH) que ha completado un estudio de fase 1 para el tratamiento de enfermedades causadas por un exceso de ACTH, como la hiperplasia suprarrenal congénita y la enfermedad de Cushing; y CRN09682, un conjugado farmacológico no peptídico para tumores sólidos SST2 positivos.
Resumen de fundamentos de Crinetics Pharmaceuticals, Inc.
| Estadísticas fundamentales de CRNX | |
|---|---|
| Capitalización bursátil | US$4.45b |
| Beneficios(TTM) | -US$496.39m |
| Ingresos (TTM) | US$18.07m |
¿Está CRNX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CRNX | |
|---|---|
| Ingresos | US$18.07m |
| Coste de los ingresos | US$357.18m |
| Beneficio bruto | -US$339.11m |
| Otros gastos | US$157.28m |
| Beneficios | -US$496.39m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Aug 04, 2026
| Beneficios por acción (BPA) | -4.71 |
| Margen bruto | -1,876.73% |
| Margen de beneficio neto | -2,747.18% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado CRNX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 05:48 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Crinetics Pharmaceuticals, Inc. está cubierta por 22 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |